

North Yorkshire & York Area Prescribing Committee

Wednesday 7th July 2021
2pm – 5.15pm, virtual meeting via Microsoft Teams

Present

Name	Job Title	Organisation	Jul 2021	Aug 2021	Sep 2021	Oct 2021
Ken Latta	Head of Medicines Optimisation	North Yorkshire CCG	Y			
Dr Tim Rider	GP Prescribing Lead	North Yorkshire CCG	Y			
TBC	GP	North Yorkshire CCG	X			
Laura Angus	Head of Medicines Optimisation	Vale of York CCG	Y			
Dr Shaun O'Connell	GP Lead for Acute Service Transformation	Vale of York CCG	Y			
Dr William Ovenden	GP	Vale of York CCG	Apols			
Kate Woodrow	Chief Pharmacist	Harrogate and District NHS Foundation Trust	Y			
Dr Ben Walker	Consultant and D&T Chair	Harrogate and District NHS Foundation Trust	Y			
Dr S Brotheridge	Consultant	Harrogate and District NHS Foundation Trust	X			
Stuart Parkes	Chief Pharmacist	York Teaching Hospitals NHS Foundation Trust	Y			
Dr Peter Hall	Consultant and D&T Chair	York Teaching Hospitals NHS Foundation Trust	Apols			
Dr Chris Hayes	Consultant	York Teaching Hospitals NHS Foundation Trust	Y			
Tracy Percival	Formulary Pharmacist	South Tees Hospitals NHS Foundation Trust	Y			
	Consultant	South Tees Hospitals NHS Foundation Trust	X			
Richard Morris	Deputy Chief Pharmacist	Tees, Esk and Wear Valleys NHS Foundation Trust	Y			
Shona McIlrae	Consultant Psychiatrist	Tees, Esk and Wear Valleys NHS Foundation Trust	Apols			
Angela Hall	Public Health representative	North Yorkshire County Council	Y (till 4.30pm)			
Anita Dobson	Public Health representative	City of York Council	Apols			
Alison Levin	Finance representative	North Yorkshire CCG	Y (till 4.45pm)			
Steve Jordan	Contracting representative	North Yorkshire CCG	Y (till 4.30pm)			
Hazel Mitford	Lay/patient representative		Y			
In attendance (non-voting membership):						
Gavin Mankin (Professional Secretary)	Principal Pharmacist Medicines Management	Regional Drug & Therapeutics Centre, Newcastle	Y			
Chris Ranson	Lead Medicines Management Pharmacist: Commissioning and Formulary	North Yorkshire CCG	Y			
Faisal Majothi / Jamal Hussain	Medicines Optimisation Pharmacist	Vale of York CCG	Y			
Jane Crewe	Formulary Pharmacist	York Teaching Hospitals NHS Foundation Trust	Y			
Sara Abbas-	Formulary Pharmacist	Harrogate and District NHS Foundation Trust	X			

Llewelyn / Emily Parkes						
Ian Dean	LPC Representative		Y (till 4.30pm)			
Dr Sally Tyrer	LMC Representative		Apols			
Sara Moore	Deputy Chief Pharmacist	Harrogate and District NHS Foundation Trust	Y (till 4pm)			
Chris Williams	Chief Pharmacist	Tees, Esk and Wear Valleys NHS Foundation Trust	Y			

In attendance

Emily Brown (RDTC) – to facilitate sharing of papers on MS Teams

Daniel Newsome (RDTC) - Principal Pharmacist Medicines Management – supporting professional secretary as required.

The meeting was quorate with 13 out of 18 currently appointed voting members in attendance.

APC members and attendees were reminded to keep detailed discussions confidential to allow free and full debate to inform unencumbered decision making. Discretion should be used when discussing meetings with non-attendees and papers should not be shared without agreement of the chair or professional secretary, to ensure confidentiality is maintained.

The meeting was chaired until item 5 by the RDTC after which Dr Tim Rider chaired the meeting.

Part 1

1. Welcome to New APC

Ken Latta and the Professional Secretary welcomed members to the first meeting of the new North Yorkshire & York APC, and a round of introductions were made

2. Apologies for absence:

William Ovenden, Peter Hall, Shona McIlrae, Anita Dobson, Sally Tyrer

3. Declarations of Interest

Shaun O’Connell/Laura Angus - are in a relationship This has been fully declared to Vale of York CCG and the CEO and legal adviser deemed it not a conflict of interest for them to continue as members of MCC.

Shaun O’Connell – consultancy work for various pharma companies none of which relevant to today’s agenda.

Kate Woodrow – Vice-Chair of Leeds Research Ethics Committee.

Ben Walker – advisory boards for various pharma companies none of which relevant to today’s agenda, and dermatology undertakes clinical trials with funding going to HDFT.

Stuart Parkes - advisory boards for various pharma companies none of which relevant to today’s agenda, and wife is high cost drugs pharmacist at HDFT.

Tim Rider – GP partner in a dispensing practice and interest in an online pharmacy.

Chris Hayes - advisory boards/educational events for various pharma companies none of which relevant to today's agenda.

Laura Angus - Council Member of PrescQIPP, MTech Access Associate (Not in relation to any specific product/medicine or company), Consultant work with Pharmacy Management Academy, Interim Lead Pharmacist for Humber, Coast and Vale ICS, and participant in NHSE/I NExT Director Scheme, shadowing the board, in a Non-executive capacity, at HDFT.

Jamal Hussain - Associate to MTech Access, sister is a practice pharmacist at a GP in VoY, and starting a new employment with Abbott Laboratories in part of their market access team for Freestyle Libre in September 2021. I was due to start officially with NECs from 1st of July but in light of me moving to Abbott we decided I could work my notice period in VoY.

The APC agreed that none of the interests declared above were an issue for items on today's agenda.

Declarations of interest:

The Chair reminded subgroup members of their obligation to declare any interest they may have on any issue arising at committee meetings which might conflict with the business of the APC.

Declarations declared by members of the APC are listed in the APC's Register of Interests. The Register is available via the professional secretary.

Declarations of interest from today's meeting:

None declared

4. Nominations and Appointment of APC Chair

Following a unanimous vote by voting members Dr Shaun O'Connell and Dr Tim Rider were appointed as the new APC Co-Chair and Stuart Parkes as Deputy Chair.

5. APC Terms of Reference Including Governance Arrangements

The draft APC Terms of Reference were presented to the APC and following amendments were proposed:

- Section 1 – add South Tees Trust
- Section 2 – add to liaise with local authorities on medicines related issues that relate to services that they commission, and to support and co-ordinate responses to recommendations on medication safety made by stakeholder organisations as part of an overall risk management strategy.
- 3.5 – change to: The quorum is reached when at least two thirds of voting members are present. An appropriate spread of members' interests is also required for the quorum to be valid. It is advisable that, at least one member from Harrogate & District NHS Foundation Trust (HDFT), one member from York Teaching Hospitals NHS Foundation Trust each Provider trust, one member from each CCG, and a sufficient presence of members with an appropriate clinical knowledge need to be present. TEWVFT to be present for any items pertaining to mental health on the agenda. South Tees Hospitals Foundation Trust to be present for any items relating to services provided by them for North Yorkshire patients.
- 3.8 – change to: Other advisory specialists may be invited to attend where specific issues relating to their respective areas of responsibility are discussed (e.g. those submitting papers or pathways for approval) as agreed following discussion between the Co-Chairs and Professional Secretary.
- Section 4 – add APC members are expected to attend at least 9 out of 12 meetings.
- Section 8 – add Appeals will only be accepted from clinicians within stakeholder organisations of the APC, The right to an appeal will be at the Chair's discretion following discussion with the Professional Secretary, Decision appears to be based on inaccurate or incomplete information in formulary application or papers submitted to APC, Decision is based on upon incomplete presentation of formulary application, guideline or agenda item to APC, Appeals against APC decisions will not be accepted directly from pharmaceutical

industry, and The clinician submitting the appeal may be invited to attend the APC in support of the appeal.

- 9.5 – change to: The APC will not make a recommendation on any drug due a NICE TA in the next 6 months, and no decision will be based on draft NICE Guidelines or Technology Appraisals.

ACTION:

- **RDTTC to make required changes to APC ToR and bring final version to August 2021 APC for approval.**

6. How the New APC Will Operate and Proposed Future Process for NY&Y APC

An overview of the decision making processes of the APC was presented to and approved by the APC. The importance of clear timescales/deadlines when consulting on guidelines/formulary applications prior to submission to APC for approval with all stakeholder organisation was discussed to ensure unnecessary delays. It was agreed these timescales should be agreed between those producing the formulary submission/guideline as this may vary depending on the item in question. The importance of making the right decision and ensuring full/proper consultation was agreed.

7. Minutes of Previous APC/MCC & Decision Summary of Meetings Held June 2021 (+outcome of NY/VoY CCG exec)

The minutes of the June 2021 Y&S MCC and Harrogate APC were received for information.

It was noted that the VoY CCG CE committee has approved the recommendations from the June 2021 MCC Meeting.

8. Outstanding Action Logs

The APC received the discussed the outstanding action logs from Y&S MCC and Harrogate APC for information.

The Co-Chairs and professional secretary will review these action logs and agree which ones need to brought forward to the action log/agenda of the new APC.

ACTION:

- **The Co-Chairs and professional secretary will review action logs from Y&S MCC and Harrogate APC and agree which ones need to brought forward to the action log/agenda of the new APC.**

Part 2 – Governance

9. APC Declarations of Interest Policy

A draft Declarations of Interest Policy for the APC and its subgroups was presented to and approved by the APC. The policy is intended to ensure that the decision making of the North Yorkshire & York Area Prescribing Committee is of the highest standard and is open, transparent and any potential or actual conflicts of interest are declared by members. It is based on existing polices from GMMMG, County Durham & Tees Valley, North of Tyne, NTAG and the previous Y&S MCC policy.

ACTION:

- **RDTTC to circulate and publish final approved version of Declarations of Interest Policy.**
- **RDTTC to circulate Annual Declarations of Interest Form to members for completion prior to August 2021 APC meeting.**

10. APC Formulary Application Form Template

The APC discussed the new North Yorkshire & York APC Formulary Application Form Template.

It was agreed to make the following changes before bringing a final draft to the August 2021 APC meeting for approval:

- Part 1 – add The manufacturer/ supplier may provide information supporting the application, but the application must come from a clinician working within one of the APC stakeholder organisations, and Full clinical evidence does not to be submitted or completed for NICE TA approved drugs just the sections on finance and how introduction of the drug will be managed locally.
- Part 2 – add Incomplete applications will not be considered by the APC.
- 4.1 – add Manufacturer signed up to All Trials Petition?
- 4.1 – clarify AMBER SI/SR RAG status
- Part 6 – add: include copies of supporting evidence as PDFs with completed application form.
- Incorporate the details of the individuals involved with the consultation prior to submitting the application

The committee discussed the ambition of moving to an electronic formulary application process, and felt that this should be a future objective.

ACTION:

- **RDTC to make requested changes to Formulary Application Form Template and bring back to August 2021 APC for approval.**

11. APC Shared Care Guideline Template

The APC approved the new North Yorkshire & York APC Shared Care Template. This is based on the template currently used in both Harrogate and York, as well as the new national RMOC shared care template. The scope for local amendments was noted. It was felt important to adopt what is a nationally agreed template and process from RMOC, but accepted there will be a significant amount of work involved with their local implementation

ACTION:

- **RDTC to arrange for approved Shared Care Template to be added APC website.**

12. APC Cover Sheet for Agenda Items Template

The APC approved the new North Yorkshire & York APC Cover Sheet for Agenda Items Template. This is based on the template currently used in Y&S MCC and North Yorkshire CCG. The APC agreed that a cover sheet was not necessary for formulary amendments where an APC application form has been completed.

ACTION:

- **RDTC to circulate final approved version of APC Cover Sheet for Agenda Items Template.**

Part 3 – Mental Health

13. TEWV Drug & Therapeutics Committee Feedback – May 2021

CW/RM presented to the APC a briefing report highlighting the main issues discussed at the recent TEWV D&T.

14. TEWV STOMP medication pathway – draft

Matthew Croft (TEWV) in attendance for agenda item.

A draft pathway from TEWV designed to enhance the national guidance on STOMP providing greater advice for primary care was presented to the APC. It was explained that this resource is aimed at primary care and the APC were asked to raise awareness of its existence within the sector.

The APC welcomed the document and were in agreement with its content.

ACTION:

- **JC/SAL to add link to guideline on the formulary website.**

15. TEWV Depression pathway (updated)

An updated TEWV Depression pathway was presented to and approved by the APC. It has been refreshed with changes to highlight key pieces of information and amend medication options at different steps.

ACTION:

- **JC/SAL to add link to guideline on the formulary website.**

16. TEWV Anxiety pathway (updated)

An updated TEWV Anxiety pathway was presented to and approved by the APC. It has been refreshed with changes to highlight key pieces of information and amend medication options at different steps.

ACTION:

- **JC/SAL to add link to guideline on the formulary website.**

17. TEWV Adult ADHD algorithm (updated)

An updated TEWV Adult ADHD algorithm with some minor amendments was presented to and approved by the APC.

ACTION:

- **JC/SAL to add link to guideline on the formulary website.**

18. TEWV Children's ADHD algorithm (updated)

An updated TEWV Children's ADHD algorithm with some minor amendments was presented to and approved by the APC.

ACTION:

- **JC/SAL to add link to guideline on the formulary website.**

Part 4 – Formulary Issues

19. Appeals Against Previous APC Decisions

None received.

20. Process for Harmonising Harrogate and Y&S Formularies

The Area Prescribing committee discussed the process being undertaken to align the drug formularies. This is being undertaken BNF chapter by chapter, prioritizing those chapters in which most prescribing takes place. A subgroup has been formed to progress this work. Also looking to move to single formulary covering the whole APC hosted on netformulary but in the interim separate but aligned formularies will be maintained by HDFT and YFT.

21. Formulary NICE TAs and MHRA Drug Safety Update – June 2021

The drugs in the following TAs to be reflected in the formulary as RED drugs in the relevant chapters with links to the TAs:

- TA705: Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer
- TA707: Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer
- TA709: Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency

- TA710: Ravulizumab for treating atypical haemolytic uraemic syndrome

The drugs in the following TAs to be reflected in the formulary as NOT APPROVED for this indication in the relevant chapters with links to the TAs:

- TA706: Ozanimod for treating relapsing–remitting multiple sclerosis

All of the above TAs are NHSE-commissioned, therefore would have no cost impact to CCGs.

The drugs in the following TAs are CCG-commissioned and to be reflected in the formulary as RED drugs in the relevant chapters with links to the TAs:

- TA708: Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis
- TA711: Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs

Medicines Safety (MHRA drug safety update – June 2021

The group noted the drug safety updates for June 2021. The links are to be added to the relevant sections of the formulary.

ACTION:

- **JC/ABS to update the formulary websites with the approved changes once approved by VoY CCG.**

22. Other Formulary Issues

Bempedoic acid

The Addition of Bempedoic acid to the local formulary is still in hold due to the need to confirm what to do about patients in whom the statin dose cannot be increased to usual max but they remain on statin, and hence does the mean such patients would on triple therapy (sub-optimal statin + ezetimibe + bempedoic acid). NICE TA would appear not to cover this group of patients. Also need to confirm how this relates to use of PCSK-9 inhibitors.

SOC has contacted NICE and NICE have confirmed that they are in the process of requesting changes and updates to (hopefully) address the issue you outlined via the lipid management pathway/algorithms provided by NHS England (& endorsed by NICE).

It was noted that the 90 day deadline for implementation of this NICE TA is the 28th July 2021.

NHSE Clinical Commissioning Urgent Policy Statement Subcutaneous copper histidinate injections for presymptomatic neonates with classical Menkes disease

The APC discussed and agreed that this NHSE Policy was not relevant to the local formulary. Those drugs with an NHSE Clinical Commissioning Policy will be brought to APC for information so that the RAG status can be included on the local formulary.

23. New Drug Applications

Nil this month.

24. Single one-off patient non-formulary patient requests

Nil this month.

25. Compassionate Use/Free of Charge Scheme Requests

Nil this month.

26. NTAG Update

Nil this month.

27. RMOC Update

Nil this month.

Part 5 – Shared Care and Guidelines (non-Mental Health)

28. Shared Care Guidelines for Approval

Nil this month.

29. Draft guidance for feedback - Private Healthcare providers requesting prescriptions from GP services

The Regional Drugs and Therapeutics Centre (RDTC) has produced draft advisory guidance on 'Private Healthcare providers requesting prescriptions from GP services' (attached) on behalf of RMOC North. APC members were asked to submit any comments on the document to the RDTC which will feed into the national consultation process being undertaken by the RMOC/NHS Clinical Commissioners.

30. Psoriatic arthritis pathway

An updated version from YFT to include of guselkumab as per NICE TA was presented to and approved by the APC subject to all appropriate stakeholder logs plus version control being added.

ACTION:

- **SP to add appropriate stakeholder logos plus version control to Psoriatic arthritis pathway**
- **JC/ABS to update the formulary websites with link to pathway once approved by VoY CCG.**

Part 6 – Other Items of Business

31. Steroid Emergency Cards

In August 2020 NHS England and Improvement issued a national patient safety alert (NatPSA) promoting the use of a new Steroid Emergency Card (in addition to the existing blue steroid card) to support the early recognition and treatment of adrenal crisis in adults.

The purpose of this local document on 'When to Issue a Steroid Card' is to offer guidance to prescribers and dispensers of steroids, based on the SPS and PrescQIPP guidance, with local expert opinion sought for those points where there is no hard evidence in the medical literature. It is in poster format and designed to be displayed as a concise summary on when to issue a steroid card in clinics and dispensaries

The local document on 'When to Issue a Steroid Card' was approved by the APC.

32. Antibiotic Issues

Nil this month.

33. APC Workplan

Item not discussed.

Part 7 – Standing Items (for information only)

34. TEWV D&T Minutes – March 2021

Circulated for information.

35. York & Scarborough Trust Drug and Therapeutics Committee Minutes

Latest minutes not yet available.

36. Harrogate Trust Medicines and Therapeutics Group Minutes – July 2021

First meeting of this new group is at end of July 2021.

37. **Hull and East Riding Prescribing Committee (HERPC) minutes – May 2021**
Latest minutes not yet available.
38. **County Durham & Tees Valley APC Minutes – May 2021**
Circulated for information.
39. **West Yorkshire & Harrogate ICS APC Minutes – April 2021**
Circulated for information.
40. **RDTC Monthly Horizon scanning – June 2021**
Circulated for information.

Chairman's Action

Nil this month

Any Other Business

Dapagliflozin in CKD

The APC discussed interest locally from renal teams in prescribing for CKD ahead of NICE TA and dapagliflozin being licensed for this indication. The APC agreed that if clinicians wish to initiate for this indication then a formal formulary submission was required but as NICE TA is due within next 6 months APC would wish to wait for final NICE TA to be published.

The NICE TA is due in January 2022 and the EMA granted positive opinion for this indication on 24.6.21 but not known if MHRA will adopt this positive opinion.

Date and time of next meeting

Wednesday 4th August 2021, 2pm – 4.30pm, Virtual Meeting via Microsoft Teams